Research blood draws

PROCEDURE3 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Medical University of South Carolina, Pfizer

Conditions

Cholangiocellular CarcinomaCholangiolar CarcinomaDisease ProgressionIntrahepatic CholangiocarcinomaPeripheral CholangiocarcinomaSolid Tumor, Adult

Phase 2

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

CompletedNCT01862315

Memorial Sloan Kettering Cancer CenterCholangiocellular Carcinoma, Cholangiolar Carcinoma, Intrahepatic Cholangiocarcinoma +1

Start: 2013-05-31End: 2025-03-18Updated: 2025-03-19

Unknown Phase

Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC

CompletedNCT03302325

Medical University of South CarolinaSolid Tumor, Adult

Start: 2017-10-12End: 2020-01-06Updated: 2024-09-19

Treatment Resistance Following Anti-cancer Therapies

TerminatedNCT04436120

PfizerDisease Progression

Start: 2019-02-13End: 2020-12-14Updated: 2024-12-03

Related Papers

A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).

Journal of Clinical Oncology2018-05-209 citations